Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta)

自体CD19指导的嵌合抗原受体CAR-T细胞疗法（University of Alberta）

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAutologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Source of cells > Blood-derived +[4]

Mechanisms of ActionT lymphocyte replacementsAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Alberta

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Alberta

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A